Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19,603,857
-
Total 13F shares
-
20,964
-
Share change
-
+20,964
-
Total reported value
-
$101,378
-
Price per share
-
$4.84
-
Number of holders
-
7
-
Value change
-
+$101,378
-
Number of buys
-
7
Institutional Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) as of Q1 2023
As of 31 Mar 2023,
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,964 shares.
The largest 7 holders included
Virtu Financial LLC, Powell Investment Advisors, LLC, UBS Group AG, BlackRock Inc., Tower Research Capital LLC (TRC), WOLVERINE ASSET MANAGEMENT LLC, and WELLS FARGO & COMPANY/MN.
This page lists
7
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.